Harbour Investments Inc. Buys 1,046 Shares of DexCom, Inc. (NASDAQ:DXCM)

Harbour Investments Inc. raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 8.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 12,895 shares of the medical device company’s stock after purchasing an additional 1,046 shares during the period. Harbour Investments Inc.’s holdings in DexCom were worth $864,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in DXCM. Crewe Advisors LLC purchased a new stake in shares of DexCom during the 1st quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in DexCom in the 2nd quarter valued at about $25,000. Sachetta LLC grew its stake in DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after acquiring an additional 171 shares in the last quarter. DT Investment Partners LLC increased its position in shares of DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after acquiring an additional 315 shares during the period. Finally, Riverview Trust Co raised its stake in shares of DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on DXCM shares. Leerink Partners lowered their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Sanford C. Bernstein upped their price objective on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Barclays dropped their price objective on DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research report on Monday, July 29th. Morgan Stanley reduced their target price on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a report on Friday, July 26th. Finally, Piper Sandler restated an “overweight” rating and issued a $90.00 price target on shares of DexCom in a report on Monday, August 26th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $104.59.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. The trade was a 0.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.30% of the company’s stock.

DexCom Trading Up 1.6 %

NASDAQ:DXCM opened at $75.88 on Friday. The company has a market capitalization of $29.64 billion, a P/E ratio of 45.36, a PEG ratio of 2.22 and a beta of 1.17. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The firm has a fifty day simple moving average of $69.89 and a 200-day simple moving average of $92.01.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.